Introduction {#s01}
============

The initial discovery of antidepressive effects of three-ring structures that inhibited monoamine transporters (tricyclic antidepressants \[TCAs\]; [@bib49]; [@bib6]) catalyzed the search for drugs that selectively inhibit one monoamine transporter over another and led to the development of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors ([@bib33]). TCAs and SSRIs in particular have been the mainstays of pharmacological intervention for depression- and anxiety-related disorders.

The specific monoamine transporter inhibitors inhibit neurotransmitter uptake with *K*~i~s in the nanomolar range ([@bib19]; [@bib79]), with additional direct and/or downstream effects ([@bib68]; [@bib8]; [@bib66]). It remains unclear, however, how TCAs and SSRIs, or any treatment for depression, achieve their clinical results, reflecting the complex neural circuitry that underlies the disease pathology. Notably, TCAs and SSRIs have low-affinity interactions with a diverse group of membrane proteins ([@bib65]; [@bib11]; see also Table S1), which may provide additional mechanisms for altering neural chemistry and circuitry ([@bib21]). The mechanisms underlying this polypharmacology remain unclear, but integral membrane proteins have two things in common: they are membrane spanning, and their activity can be modulated by changes in lipid bilayer properties (curvature, thickness, and elasticity) that can be induced by the addition of amphiphiles, including many biologically active molecules (e.g., a variety of toxins; [@bib76]; [@bib20]), currently used or discontinued drugs ([@bib69], [@bib70]), and phytochemicals ([@bib43]; see also [@bib54], Table 3).

This bilayer-dependent regulation of membrane protein function by amphiphiles arises because (1) the conformational changes that underlie membrane protein function involve their bilayer-spanning domains and (2) membrane-embedded proteins locally organize their surrounding bilayer ([@bib54]; see also [Fig. 1](#fig1){ref-type="fig"}).

![**Membrane proteins are energetically coupled to the lipid bilayer. (A)** Schematic depiction of an ion channel that can exist in an inactive (closed) state and an active (open) state. The hydrophobic length of the two conformers differ, with the open state having the shorter hydrophobic length, leading to a hydrophobic mismatch between the protein's hydrophobic domain and the bilayer hydrophobic core. In response, the bilayer adjusts by compressing and bending the surrounding lipids, which incurs an energetic cost. This bilayer deformation energy, as well as any residual mismatch energy ([@bib58]), will contribute to the equilibrium between the two conformational states and varies with changes in bilayer material properties, which can be altered by adsorption of small amphiphilic molecules. **(B)** Schematic depiction of gA channel formation. gA is a pentadecapeptide with β^6.3^-helical structure that dimerizes to form a transmembrane channel. The association/dissociation of the channel can be observed as changes in the single-channel current. The length of the conducting channel is less than the thickness of the bilayer, causing gramicidin channel activity (lifetime and frequency of appearance) to be dependent on the bilayer deformation energy. Changes in bilayer properties are observed as changes in lifetime and frequency.](JGP_201812263_Fig1){#fig1}

This bilayer deformation has an energetic cost (Δ*G*~def~) that depends on the protein--bilayer interface and varies with changes in bilayer material properties, such that the energetics of membrane protein conformational changes (e.g., a closed↔open \[C↔O\] transition in an ion channel; [Fig. 1 A](#fig1){ref-type="fig"}) will include a contribution from the bilayer: $\Delta G_{bilayer}^{C\rightarrow O} = \Delta G_{def}^{O} - \Delta G_{def}^{C}.$ The total free energy change associated with the C↔O transition thus will be the sum of contributions intrinsic to the protein, $\Delta G_{protein}^{C\rightarrow O},$ and contributions from the bilayer, $\Delta G_{bilayer}^{C\rightarrow O}$:$$\Delta G_{total}^{C\rightarrow O} = \Delta G_{protein}^{C\rightarrow O} + \left( {\Delta G_{def}^{O} - \Delta G_{def}^{C}} \right) = \Delta G_{protein}^{C\rightarrow O} + \Delta G_{bilayer}^{C\rightarrow O}.$$To determine whether antidepressants (ADs) in fact alter lipid bilayer properties, as sensed by bilayer-spanning channels, we used gramicidin A (gA) channels as probes to assess for drug-induced changes in bilayer properties ([@bib37]; [@bib45]; [@bib55],[@bib54]; [@bib69]). gA forms conducting channels ([Fig. 1 B](#fig1){ref-type="fig"}) when two nonconducting monomers dimerize to form the transmembrane dimer (2 M ↔ D).The length (*l*) of the dimer (channel) is less than the thickness of the unperturbed bilayer (*d*~0~), resulting in hydrophobic mismatch, meaning that channel formation causes a local bilayer deformation with an associated Δ*G*~def~ (e.g., [@bib35]; [@bib61]; [@bib54]). The bilayer responds by imposing a disjoining force (*F*~dis~) on the dimer, such that changes in Δ*G*~def~ (in $\Delta G_{bilayer}^{M\rightarrow D}$) are reflected as changes in the kinetics of channel formation (and are observed as altered single-channel lifetimes and appearance rates \[the single-channel lifetime and channel appearance rate decrease as the disjoining force increases\]). This renders gA channels sensitive to their host membrane environment and useful as probes of changes in bilayer properties ([@bib54]); decreases in bilayer thickness, increases in bilayer elasticity, and/or a more positive intrinsic curvature will decrease Δ*G*~def~ and increase gA channel appearance frequencies (*f*) and lifetimes (τ).

Despite compelling evidence that ADs interact with membranes (e.g., [@bib24]), little is known about their bilayer-modifying effects other than that they tend to increase bilayer fluidity, and changes in fluidity are unlikely to be primary determinants of changes in membrane protein function ([@bib50]), as they do not cause changes in the equilibrium distribution between conformational states. We therefore examined a library of 21 TCAs and SSRIs (see Table S2 for the structures, pKas, and calculated LogPs \[cLogPs\]) for their bilayer-modifying effects using the gA channels as probes, which allows us to quantify how the ADs alter the bilayer contribution to the gA monomer↔dimer equilibrium ($\Delta G_{bilayer}^{M\rightarrow D}$) as a global measure of the changes in bilayer properties. All 21 compounds shifted the gA monomer--dimer equilibrium toward the conducting dimers. Among the ADs examined, fluoxetine, paroxetine, and sertraline were the most bilayer-modifying compounds and zimelidine, citalopram, and alaproclate the least.

The rank order of bilayer-modifying potency was not satisfactorily predicted by the compounds' hydrophobicity, as estimated using the cLogP or calculated LogD at pH 7.0 (cLogD~7~). The order was predicted quite well by the compounds' bilayer/electrolyte partition coefficients measured using isothermal titration calorimetry (ITC). Using single-channel electrophysiology, we find that the TCAs amitriptyline and imipramine and the SSRI citalopram altered primarily intrinsic curvature, and the SSRI fluoxetine altered primarily bilayer elasticity. Our results provide a novel mechanism for the ADs' off-target effects and further show that a compound's bilayer-modifying potency depends on its mole fraction in the membrane as well as its molecular structure.

Materials and methods {#s02}
=====================

Materials {#s03}
---------

1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC), and 1,2-dierucoyl-*sn*-glycero-3-phosphocholine (DC22:1PC) were from Avanti Polar Lipids. *n*-decane (99.9% pure) was from ChemSampCo.

For the fluorescence experiments, we used a mixture of gramicidins A, B, and C isoforms purchased from Sigma Chemical Co. For the single-channel experiments, we used the 15-amino-acid analogue \[Ala^1^\]gA (AgA(15)) and the chain-shortened enantiomer des-(D-Val-Gly)gA^−^ (gA^−^(13)), which were synthesized and purified as described previously ([@bib27]).

The fluorophore 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS) disodium salt was from Invitrogen. Extravesicular ANTS was removed using PD-10 desalting columns from GE Healthcare.

Citalopram (+/−), citalopram (S+), and citalopram (R−) were gifts from H. Lundbeck A/S (Copenhagen, Denmark). All other drugs were from Sigma Chemical Co. and were of the highest available purity. All stocks were prepared in DMSO (Burdick and Jackson).

Methods {#s04}
-------

### Gramicidin-based fluorescence assay {#s05}

The gramicidin-based fluorescence assay has been described previously ([@bib41]; [@bib38]). In brief, large unilamellar vesicles (LUVs), loaded with intravesicular ANTS (diameter, 150 ± 50 nm; [@bib38]) were prepared from DC~22:1~PC and gramicidin (gD) using freeze-drying, extrusion, and size-exclusion chromatography; the final lipid concentration was 4--5 mM, and the suspension was stored in the dark at 12.5°C for a maximum of 7 d. Before use, the LUV-ANTS stock was diluted to 200--250 µM lipid with NaNO~3~ buffer (140 mM NaNO~3~ and 10 mM HEPES, pH 7) and incubated with 260 nM gD for 24 h to allow the gramicidin monomers to cross the vesicle membrane.

The AD (dissolved in DMSO) or DMSO (as control) was added to a LUV-ANTS sample and equilibrated at 25°C in the dark for 10 min before the mixture was loaded onto a stopped-flow spectrofluorometer (SX.20; Applied Photophysics) and mixed with either NaNO~3~ buffer or TlNO~3~ buffer (Tl^+^ \[thallous ion\] is a gramicidin channel-permeant quencher of ANTS fluorescence). Samples were excited at 352 nm, and the fluorescence signal above 455 nm was recorded in the absence (four successive trials) or presence (nine successive trials) of the quencher. All ADs fluoresce to varying degrees, and the addition of these drugs to LUVs in control experiments without gA or Tl^+^ increased the fluorescence signal. The instrument has a dead time of \<2 ms, and the next 2- to 100-ms segment of each fluorescence quench trace was fitted to a stretched exponential, which is a computationally efficient way to represent a sum of exponentials with a distribution of time constants, reflecting the distribution of LUV radii and number of gD channels in their membranes (e.g., [@bib9]):$$F(t) = F(\infty) + \left\lbrack {F(0) - F(\infty)} \right\rbrack \cdot \left\{ {\exp - {(t/\tau)}^{\beta}} \right\},$$where *F*(t) denotes the fluorescence intensity as a function of time, t; τ is a parameter with units of time; and β (0 \< β ≤ 1, where β = 1 denotes a homogenous sample) is a measure of the LUV dispersity. The rate of Tl^+^ influx was determined at 2 ms ([@bib9]):$$k(t) = \frac{\beta}{\tau} \cdot \left. \left( \frac{t}{\tau} \right)^{\beta - 1} \right|_{2{ms}}.$$The quench rate for each experiment represents the average influx rate of the trials with Tl^+^. The quench rate was normalized to the rate in control experiment without drug, and the reported values represent averages from three or more experiments.

### ITC {#s06}

The binding of ADs to lipid vesicles was determined by measuring the heats of partitioning using an Auto-iTC~200~ isothermal titration calorimeter (Microcal) with 200 µl sample cell volume and 40 µl syringe volume. DC~22:1~PC LUVs without ANTS or gA were rehydrated in the same NaNO~3~ buffer as in the fluorescence assay. ADs were diluted from DMSO stock with NaNO~3~ buffer. The DMSO concentration was kept ≤1% and was matched between the lipid and drug samples to minimize any effects of the heats of dilution.

ADs were added to the sample cell and titrated with the DC~22:1~PC LUV suspension. The drug and lipid concentrations for each drug--lipid titration were optimized to give a large signal with a wide dynamic range that eventually saturated; control injections of LUVs into a drug-free cell produced minimal heat signals. An initial injection of 0.2 µl was discarded during the analysis to allow for cell--syringe equilibration artifacts. Then, 19 2-µl injections of the lipid suspension were spaced sufficiently apart (≥150 s) to ensure that the signal returned to baseline between injections. The enthalpy change generated by injection *i* ($h_{AD}^{W\rightarrow L}(i)$) was determined by integrating the area under the curve of that injection using Origin 7 (OriginLab), as adapted by Microcal, for ITC data analysis.

Solute binding to lipid bilayers can be described as partitioning between two immiscible phases, which can be analyzed using different frameworks ([@bib63]; [@bib28]; see also online supplemental material). Because ADs are amines (except for alaproclate, lofepramine, and zimelidine) that have pK*~a~*s \>9, they will be positively charged at pH 7. AD binding thus will confer a positive surface charge when they partition into the lipid--electrolyte interface, and their binding to lipid bilayers is conveniently analyzed as adsorption to the bilayer--electrolyte interface (e.g., [@bib47]), where the surface solute density in the lipid phase ($\left\{ {AD} \right\}_{L}$, in moles/area) is related to the aqueous solute concentration by an adsorption coefficient with units of length (*K*~2~):$$\left\{ {AD} \right\}_{L} = K_{2} \cdot \left\lbrack {AD} \right\rbrack_{W}.$$AD adsorption into the bilayer--electrolyte interface will give rise to a surface charge, which in turn will establish a surface potential ($\phi_{0}$), and the aqueous AD concentration at the interface (\[AD\]~0~) will differ from the bulk \[AD\]~W~ ([@bib57]):$$\left\lbrack {AD} \right\rbrack_{0} = \exp\left\{ - \frac{z_{AD} \cdot F \cdot \phi_{0}}{RT} \right\}\left\lbrack {AD} \right\rbrack_{W},$$where *z*~AD~ denotes the AD valence, *F* is Faraday's constant, *R* is the gas constant, and *T* is the temperature in degrees kelvin. The effective adsorption coefficient ($K_{2}^{eff}$) thus becomes$$K_{2}^{eff} = K_{2} \cdot \exp\left\{ - \frac{z_{AD} \cdot F \cdot \phi_{0}}{RT} \right\} = K_{2} \cdot \exp\left\{ - \beta \cdot \phi_{0} \right\},$$where $\beta = z_{AD} \cdot F/RT.$

Each injection of an aliquot (volume δ*V*) of a suspension of lipid vesicles (lipid concentration *C*~L~) into the system causes a redistribution of AD from the aqueous to the lipid phase with an ensuing heat production, $h_{AD}^{W\rightarrow L}(i).$ After *i* injections, the cumulative heat production ($\Sigma h_{AD}^{W\rightarrow L}(i)$) becomes Eq. S23 in Supplemental Material):$$\begin{array}{l}
{\Sigma h_{AD}^{W\rightarrow L}\left( i \right) = H_{AD}^{W\rightarrow L} \cdot \left\langle AD \right\rangle_{L}\left( i \right) =} \\
{H_{AD}^{W\rightarrow L} \cdot \left\langle {AD} \right\rangle_{T} \cdot \frac{K_{2} \cdot \exp\left\{ {- \beta \cdot \phi_{0}\left( i \right)} \right\} \cdot i \cdot \delta V \cdot C_{L} \cdot a_{L}}{V_{W} + i \cdot \delta V \cdot \left( 1 + K_{2} \cdot \exp\left\{ {- \beta \cdot \phi_{0}\left( i \right)} \right\} \cdot C_{L} \cdot a_{L} \right)},} \\
\end{array}$$where $H_{AD}^{W\rightarrow L}$ denotes the molar enthalpy of partitioning, $\left\langle {AD} \right\rangle_{L}(i)$ and $\left\langle {AD} \right\rangle_{T}$ are the total amount of AD in the lipid phase after the *i*th injection and in the system, respectively, $\phi_{0}\left( i \right)$ is the surface potential, *V*~W~ is the initial volume of electrolyte in the calorimeter cell, and *a*~L~ is the lipid molar area. $\phi_{0}\left( i \right)$ can be estimated using the Gouy--Chapman theory of the diffuse double layer ([@bib5]). For univalent electrolytes (Eq. S28):$$\begin{array}{l}
{\phi_{0}\left( i \right) =} \\
{\frac{2}{\beta} \cdot \arcsin\left\{ \frac{z_{AD} \cdot F}{\kappa \cdot \sqrt{C_{S}}} \cdot \frac{\Sigma h_{AD}^{W\rightarrow L}\left( i \right)}{i \cdot \delta V \cdot C_{L} \cdot a_{L} \cdot H_{AD}^{W\rightarrow L} + \Sigma h_{AD}^{W\rightarrow L}\left( i \right) \cdot a_{D}} \right\},} \\
\end{array}$$where $\kappa = \sqrt{8} \cdot RT \cdot \varepsilon \cdot \varepsilon_{0} \cdot 1,000,$ ε is the dielectric constant, ε~0~ is the permittivity of free space, *a*~D~ is the AD molar area, and *C*~S~ is the total concentration of univalent salt (the factor 1,000 converts to concentrations in moles/liter to moles/m^3^). $K_{2}{~and~}H_{AD}^{W\rightarrow L}$ could then be estimated by fitting [Eqs. 7](#e7){ref-type="disp-formula"} and [8](#e8){ref-type="disp-formula"} to the experimental $\Sigma h_{Drug}^{W\rightarrow L}(i) - i$ relations (see online supplemental material for details) using the nonlinear least-squares fitting algorithm implemented in Matlab (The MathWorks Inc.).

Single-channel experiments {#s07}
--------------------------

The single-channel bilayer punch method has been described previously ([@bib37]; [@bib45]). In brief, a bilayer composed of DC~18:1~PC suspended in *n*-decane was formed across a 1- to 1.5-mm hole in a Teflon partition and doped with gA. (The total AgA(15) concentration in the system was a few pM in the DOPC experiments; the concentration of gA^--^(13) was ∼10-fold higher.) Punch electrodes, bent 90°, with a 20- to 40-µm opening were used to isolate small membrane patches and record electrical activity.

All experiments were done in 1 M NaCl (plus 10 mM HEPES, pH 7) at 25 ± 1°C at an applied potential of ±200 mV. The current signal was recorded and amplified using a Dagan 3900A patch clamp, filtered at 5 kHz, digitized and sampled at 20 KHz by a PC/AT compatible computer, and filtered at 200--500 Hz. Single-channel events were detected using a transition-based algorithm, and single-channel lifetimes were determined as described previously ([@bib37]; [@bib45]). The average lifetimes were determined by fitting the results with single exponential distributions:$$N\left( t \right) = N\left( 0 \right) \cdot \exp\left\{ {{- t}/\tau} \right\},$$where τ denotes the average channel lifetime and *N*(*t*) the number of channels with durations longer than *t*. [Eq. 9](#e9){ref-type="disp-formula"} was fit to the lifetime distributions using the nonlinear least-squares fitting routine in Origin 6.1 or 8.1 (OriginLab).

Online supplemental material {#s08}
----------------------------

Table S1 summarizes TCAs\' and SSRIs\' effects on a number of membrane proteins. Table S2 summarizes physicochemical information about the TCAs and SSRIs tested in this study. Then follows a derivation of the analysis used in the ITC experiments. Fig. S1 shows the analysis of the ITC experiments with sertraline (an antidepressant with high partition coefficients) and paroxetine (an antidepressant with low partition coefficients); Fig. S2 summarizes the antidepressants\' effects on the conductance of AgA(15) and gA^−^(13) channels; Fig. S3 shows the residuals from the straightline fit to the results in Fig. 8 A.

Results {#s09}
=======

Fluorescence quenching experiments {#s10}
----------------------------------

We tested the 21 compounds (Table S2) using the gA-based fluorescence assay. [Fig. 2](#fig2){ref-type="fig"} shows results from an experiment with gA and increasing concentrations of racemic fluoxetine (R−/S+).

![**Effect of fluoxetine (R−/S+) on the time course of ANTS fluorescence quenching.** The gray dots represent individual experiments, with the data normalized to the maximum fluorescence in the absence of the quencher. **(A)** The red dots denote the average of the repeats for a given experimental condition. **(B)** The red line denotes a stretched exponential fit to each experiment. The blue stippled line demarcates 2 ms, where fluorescence quench rate was determined.](JGP_201812263_Fig2){#fig2}

The quench rates were quantified at 2 ms, and the results from measurements with ADs were normalized to the control experiment (no drug, only DMSO) nearest in time. [Fig. 3](#fig3){ref-type="fig"} summarizes results for 10 TCAs ([Fig. 3 A](#fig3){ref-type="fig"}) and 11 SSRIs ([Fig. 3 B](#fig3){ref-type="fig"}).

![**Summary** **of the antidepressants\' effects on ANTS fluorescence quench rates. (A)** Results for the TCAs. **(B)** Results for the SSRIs. Quench rates were quantified at 2 ms and the rates in the presence of the ADs were normalized to the control rate (no drug, only DMSO) determined in experiments nearest in time to the experiment with the AD. Only a subset of drugs, depending on their potency, were tested at the lowest (10 µM) and the highest (250 µM) concentrations.](JGP_201812263_Fig3){#fig3}

All the tested ADs increased the fluorescence quench rate, indicating they increased the number of conducting gA channels in the LUV membrane. (As we show later, in [Figs. 6](#fig6){ref-type="fig"} and S2, the ADs slightly decreased the single-channel conductance, so the increases in quench rate reflect increased numbers of channels.) Collectively, the ADs had widely varying potencies, but structurally similar compounds (amitriptyline-protriptyline-nortriptyline and imipramine-trimipramine-desipramine) tended to cluster together. There was no stereospecificity; the *R* enantiomers of fluoxetine and citalopram had the same effect on the fluorescence quench rate as their *S* counterparts.

ADs' bilayer-modifying potencies were quantified by the concentration at which the quench rate was doubled, *D*~AD~, which was determined by fitting the straight line$$\frac{Rate_{AD}}{Rate_{cntrl}} = 1 + \frac{\lbrack{AD}\rbrack}{D_{AD}}$$to the results for each compound ([@bib38]). The results are summarized, and the ADs ranked from the most potent (Fluoxetine) to the least potent (Zimelidine), as estimated from the concentrations needed to double the quench rates (*D*~AD~), in [Table 1](#tbl1){ref-type="table"}. The SSRIs are on gray background; the TCAs are on white background.

###### AD bilayer-modifying potency

  **Antidepressant**   ***D*~AD~ /µM**
  -------------------- -----------------
  Fluoxetine (S+/R−)   16
  Fluoxetine (S+)      17
  Fluoxetine (R−)      18
  Paroxetine           30
  Sertraline           32
  Clomipramine         39
  Lofepramine          42
  Protriptyline        52
  Amitriptyline        53
  Nortriptyline        61
  Trimipramine         72
  Imipramine           82
  Dothiepin            83
  Fluvoxamine          84
  Desipramine          97
  Doxepin              160
  Alaproclate          220
  Citalopram (S+/R−)   240
  Citalopram (R−)      240
  Citalopram (S+)      250
  Zimelidine           290

The most potent modifiers of gA activity (*D*~AD~ \< 50 µM) were the SSRIs sertraline, paroxetine, and fluoxetine and the two chlorinated TCAs (lofepramine and clomipramine). The least potent modifiers of gA activity (*D*~AD~ \>100 µM) were the SSRIs doxepin, citalopram, alaproclate, and zimelidine. The remaining drugs (the amitriptyline family, the imipramine family, dothiepin, and fluvoxamine) had intermediate potencies.

Though the TCAs tended to be distributed toward the middle and the SSRIs toward the extreme ends of the spectrum of bilayer-modifying potencies, both TCAs and SSRIs had representatives that cover the range of potencies. There was no correlation between drug class and tendency to alter bilayer properties.

Partitioning into the membrane (ITC) {#s11}
------------------------------------

To explore to what extent differences in the drugs' bilayer-modifying potency reflect their partitioning into bilayers, we estimated their partition coefficients from their predicted octanol/water partition coefficients (cLogP; cf. [@bib73]; [@bib56]) using the ACD/Percepta consensus algorithm ([@bib1]) and measured the adsorption coefficients ($K_{2}$) for a subset of the drugs using ITC ([@bib72]; [@bib80]; [@bib29]; [@bib77]; [@bib59]). The drug concentrations in the calorimeter cell were matched to the highest tested concentration in the fluorescence assay (100 or 250 µM). The lipid concentration in the injectate varied between 15 and 50 mM.

[Fig. 4 A](#fig4){ref-type="fig"} shows heats of reaction (partitioning) recorded when a 100-µM fluoxetine (S+) solution was titrated with 2-µl injections of a DC~22:1~PC LUV suspension (15 mM lipid). Fig. S1 shows results for paroxetine and sertraline, including the estimated changes in surface potential.

![**Partition coefficients and molar enthalpies of partitioning determined by ITC as compared with cLogP. (A)** Heats of reaction observed when 100 µM fluoxetine (S+) was titrated with 2-µl injections of 15 mM DC~22:1~PC LUVs (final lipid concentration in the cell was 2.4 mM). **(B)** The heats of binding from A were integrated to determine the cumulative reaction enthalpy (circles) for each injection. The results were fit by [Eqs. 7](#e7){ref-type="disp-formula"} and [8](#e8){ref-type="disp-formula"} (solid line) to determine *K*~2~ (= 6.5 ⋅ 10^−4^ cm) and $H_{AD}^{W\rightarrow L}$ (= --2.5 kcal/mole), R~2~ = 0.97. **(C)** $K_{1}~( = 2 \cdot K_{2}/d_{0})$ determined by ITC (left black or colored columns; colored columns denote compounds that were studied also using the electrophysiology assay) and estimated by cLogP (right gray columns; the consensus cLogP from the [@bib1]. Values represent mean ± SE; *n* ≥ 3.](JGP_201812263_Fig4){#fig4}

As fluoxetine (S+) partitioned into the LUVs at each injection, less of it became available for partitioning in subsequent additions, and the heat of reaction decreased with each injection. The cumulative reaction enthalpy ([Fig. 4 B](#fig4){ref-type="fig"}) was obtained by integrating the heats of partitioning for each injection, and the data were fit with a binding isotherm ([Eqs. 7](#e7){ref-type="disp-formula"} and [8](#e8){ref-type="disp-formula"}) to determine $K_{2}$ = 6.5 ⋅ 10^−4^ cm (R~2~ = 0.97). The average value (*n* = 6) was 9.2 ⋅ 10^−4^ ± 2 ⋅ 10^−5^ cm. For comparison to the corresponding cLogPs ([Fig. 4 C](#fig4){ref-type="fig"}), the $K_{2}$s were converted to dimensionless partition coefficients ($K_{1} = 2 \cdot K_{2}/d_{0},$ where $d_{0}$ is the bilayer thickness, 4.5 nm; [@bib51]). The cLogP estimates were consistently higher than the measured $\log K_{1}$ values. The difference between cLogP and $\log K_{1}$ varied between 0.2 for alaproclate and 1.3 for zimelidine ([Table 2](#tbl2){ref-type="table"}).

###### AD surface densities and mole fractions in the bilayer and the actual aqueous concentrations required to double the fluorescence quench rate

                                      **Estimated using*K*~1~**   **Estimated using cLogP**                               
  --------------- ----- ------ ------ --------------------------- --------------------------- ----- ------------- ------- -----
  Fluoxetine      17    3.61   4.27   5.5⋅10^−12^                 0.023                       8.7   9.0⋅10^−12^   0.037   3.5
  Paroxetine      30    3.35   3.68   6.7⋅10^−12^                 0.028                       20    9.7⋅10^−12^   0.040   15
  Sertraline      31    4.51   5.18   17⋅10^−12^                  0.068                       5.4   20⋅10^−12^    0.078   1.6
  Amitriptyline   53    3.59   4.72   14⋅10^−12^                  0.056                       32    29⋅10^−12^    0.11    9.0
  Imipramine      82    3.31   3.71   14⋅10^−12^                  0.057                       61    21⋅10^−12^    0.084   50
  Fluvoxamine     84    2.61   3.04   5.0⋅10^−12^                 0.021                       76    9.9⋅10^−12^   0.041   69
  Alaproclate     220   2.43   2.58   8.0⋅10^−12^                 0.033                       210   10⋅10^−12^    0.042   200
  Citalopram      250   2.64   3.39   12⋅10^−12^                  0.050                       230   30⋅10^−12^    0.12    200
  Zimelidine      290   2.40   3.69   9.3⋅10^−12^                 0.039                       280   24⋅10^−12^    0.092   250
  Clomipramine    39           5.29                                                                 25⋅10^−12^    0.096   1.7
  Lofepramine     42           6.26                                                                 28⋅10^−12^    0.11    0.2
  Protriptyline   52           4.70                                                                 29⋅10^−12^    0.11    9.0
  Nortriptyline   61           4.76                                                                 33⋅10^−12^    0.13    11
  Trimipramine    72           4.98                                                                 41⋅10^−12^    0.15    10
  Dothiepin       83           4.65                                                                 41⋅10^−12^    0.15    22
  Desipramine     97           4.28                                                                 37⋅10^−12^    0.14    41
  Doxepin         160          4.27                                                                 50⋅10^−12^    0.18    85

{AD}~L~, *m*~AD~ and \[AD\]~W~ were calculated from Eqs. S29--S31 using either the experimental ($K_{2} = K_{1} \cdot d_{0}/2$) or estimated ($K_{2}^{'} = 10^{cLogP} \cdot d_{0}/2$) adsorption coefficients, where cLogP is the consensus value from the ACD/Percepta PhysChem Suite. $V_{W}$ = 1.5 ml, $\left\langle {Lipid} \right\rangle_{T}$ = 37.3 μmol, $a_{L}$= 0.7 nm^2^, *d*~0~ (the DC~22:1~PC bilayer phosphate to phosphate thickness, 4.5 nm; [@bib51]), and $a_{D}$ = 0.3 nm^2^.

cLogP is thought to provide a good estimate of the bilayer partition coefficient (at least for neutral solutes; [@bib4]; [@bib73]). The TCAs and SSRIs, however, are amines that, except for lofepramine (pKa = 6.5), have at least one amine group with a basic pKa (Table S2) and thus are charged at pH 7.0 ([@bib24]). To describe the distribution of titratable compounds into octanol (as a proxy for biological membranes; e.g., [@bib81]), it has been proposed one could use ${cLogD}_{pH}~\left( = {cLog}P - \log\left\{ 1 + 10^{{pK}\text{a} - {pH}} \right\} \right)$, the calculated octanol/water partition coefficient taking into account the aqueous distribution between charged and neutral species at the given pH ([@bib10]). The relationship between the ADs' bilayer-modifying potencies and these different measures of hydrophobicity (partition coefficients) is explored in [Fig. 5](#fig5){ref-type="fig"}, where we plot the logarithm of the drug concentration needed to double the fluorescence quench rate (log*D*~AD~) versus log*K*~1~, cLogP, or cLogD~7~ (cLogD~pH~ at pH 7.0).

![**Comparing the bilayer-modifying potency of ADs with different measures of hydrophobicity (log*K*~1~ in A, cLogP in B, and cLogD~7~ in C).** The subset of drugs that were tested using ITC are highlighted in red. **(A)** The slope of the straight line fit to log*K*~1~ versus log(*D*~AD~): −1.28 ± 0.35 (R^2^ = 0.60). **(B)** The slope of the straight line fit to cLogP versus log(*D*~AD~): −1.46 ± 0.58 (R^2^ = 0.25). Without lofepramine, the slope is −1.24 ± 0.50 (R^2^ = 0.25). **(C)** Slope of the straight line fit to cLogD~7~ versus log(*D*~AD~): −0.68 ± 0.92 (R^2^ = 0.02). Without lofepramine, the slope is −0.016 ± 0.55 (R^2^ = 0.06). The values for cLogP and cLogD~7~ are from the [@bib1].](JGP_201812263_Fig5){#fig5}

There is an approximately linear correlation between log*K*~1~ and log*D*~AD~, and between cLogP and log*D*~AD~ (though the scatter in the latter makes cLogP a poor predictor of bilayer-modifying potency) and no correlation between cLogD~7~ and log*D*~AD~, suggesting that a key determinant of an AD's bilayer-modifying effect is its mole fraction in the membrane. The outlier with cLogP \>6 in [Fig. 5 B](#fig5){ref-type="fig"} and cLogD~7~ \>6 in [Fig. 5 C](#fig5){ref-type="fig"} is the TCA lofepramine. Excluding lofepramine did not change any conclusions.

The results in [Fig. 5 (A and B)](#fig5){ref-type="fig"} suggest that the ADs' bilayer-modifying effects depend on their mole fraction in bilayer, with relatively little dependence on their molecular structure, similar to previous studies with aliphatic alcohols ([@bib39]; [@bib82]). That cLogD~7~ provides such poor predictive ability ([Fig. 5 C](#fig5){ref-type="fig"}) suggests that the assumption underlying estimates of cLogD~pH~ (i.e., that the charged form of a titratable amphiphile does not partition into a hydrophobic phase) does not extend to the bilayer--solution interface, where the charged groups may reside in the interface. This is also evident in [@bib24] and our ITC results, even if the un-ionized form has a higher partition coefficient than the ionized/protonated form ([@bib25]; [@bib63]).

The association between bilayer-modifying potency and partitioning into the bilayer was further explored by calculating the AD surface density {AD}~L~ and the mole fraction (*m*~AD~) in the bilayer, along with the actual \[AD\]~W~ at the nominal *D*~AD~ in the experiments ([@bib14]; [@bib40]; [@bib69]; Eqs. S29--S31). The results (at \[AD\]~nom~ = *D*~AD~) are summarized in [Table 2](#tbl2){ref-type="table"}.

The ITC-based *K*~1~ estimates of *m*~AD~ at *D*~AD~ ranged between 0.02 and 0.07, indicating that there is less than one AD in the first shell of lipids around the channel (there are 8--10 lipid molecules in the first shell; [@bib48]; [@bib7]); the cLogP-based estimates varied widely, ranging from 0.04 to 0.18. For either estimate, the actual aqueous drug concentrations were up to sixfold less than the nominal concentration due to drug redistribution between the aqueous solution and the membrane.

Single-channel experiments {#s12}
--------------------------

We tested two TCAs, amitriptyline and imipramine, and two enantiomeric pairs of two SSRIs, fluoxetine and citalopram, using gA single-channel electrophysiology ([@bib37]; [@bib45]). DOPC/*n*-decane bilayers were doped with two gA analogues: the 15-amino-acid right-handed AgA(15) and the 13-amino-acid left-handed gA^−^(13). The opposite handedness prevents heterodimerization, and the homodimeric channels can be distinguished by their characteristic single-channel current transition amplitudes, as shown in the single-channel current traces and current transition amplitude histograms in [Fig. 6 (A and B)](#fig6){ref-type="fig"}.

![**Effect of amitriptyline on gA activity in the single-channel assay. (A)** Single-channel current traces recorded with increasing concentrations of amitriptyline added to both sides of a DC~18:1~PC/*n*-decane bilayer doped with gA^−^(13) and AgA(15). The lines denote the current transition amplitudes for gA^−^(13) (red) and AgA(15) (blue). **(B)** Current transition amplitude histograms of gA^−^(13) and AgA(15). The darker the shading, the greater the amitriptyline concentration. In the absence of the drug, the characteristic current transition peaks were 3.2 ± 0.1 pA and 2.0 ± 0.1 pA for AgA(15) and gA^−^(13), respectively. 100 µM amitriptyline shifted the two peaks to 2.8 ± 0.1 and 1.8 ± 0.1 pA. **(C and D)** Normalized single-channel survivor histograms (black, solid lines) of AgA(15) (C) and gA^−^(13) (D). The histograms were fit with single exponential distributions ([Eq. 7](#e7){ref-type="disp-formula"}; red dotted lines), with lifetimes (τ).](JGP_201812263_Fig6){#fig6}

Addition of amitriptyline to both sides of the bilayer shifted the equilibrium between gA monomers and conducting dimers toward the conducting dimers in a dose-dependent manner ([Fig. 6 A](#fig6){ref-type="fig"}). The current transition amplitude histograms ([Fig. 6 B](#fig6){ref-type="fig"}) show that amitriptyline produced a concentration-dependent increase in channel appearance rate and a decrease in the current transition amplitude for both the short gA^−^(13) and the long AgA(15) channels. All the TCAs and SSRIs thus tested decreased the current transition amplitude for both channel types (see also Fig. S2). The single-channel survivor histograms were fit by single-exponential decays ([Fig. 6, C and D](#fig6){ref-type="fig"}) and show that amitriptyline increased the gA channel lifetime without introducing new, kinetically distinct channel forms. That amitriptyline causes a distinct shift in single-channel properties of both the left- and right-handed gA channels, with no evidence for multiple channel populations (within each of the two channel types), suggests that amitriptyline does not interact directly with the conducting channels.

Consistent with the results of the fluorescence experiments, the tested compounds shifted the gA monomer↔dimer equilibrium toward the conducting dimers. The changes in single-channel lifetimes, normalized to the lifetimes in the absence of the drug (in the same experiment), are summarized in [Fig. 7 (A and B)](#fig7){ref-type="fig"}.

![**Summary of effects of ADs on gA channel activity in the single-channel assay. (A and B)** Normalized (A) AgA(15) and (B) gA^−^(13) lifetimes, τ~AD,15~/τ~cntrl,15~ and τ~AD,13~/τ~cntrl,13~, respectively, with increasing concentration of the given AD. The colors represent different ADs: amitriptyline (purple), imipramine (pink), fluoxetine (S+; red), fluoxetine (R−; orange), citalopram (S+; blue), citalopram (R−; green).. **(C)** The ratio of normalized gA^−^(13) versus the normalized AgA(15) single-channel lifetimes at different drug concentrations. A ratio \>1 (denoted by the dashed line) indicates a greater effect on channels formed by the shorter gA analogue by the given drug at that concentration. Values represent mean ± SE; *n* = 3--4.](JGP_201812263_Fig7){#fig7}

The fluoxetine enantiomers had the greatest effect on gA channel lifetimes for both long AgA(15) (τ~AD,15~/τ~cntrl,15~) and short gA^--^(13) (τ~AD,13~/τ~cntrl,13~) channels (τ~AD,15~/τ~cntrl,15~ = 2.3 ± 0.3 and 2.3 ± 0.3, and τ~AD,13~/τ~cntrl,13~ = 2.9 ± 0.4 and 3.1 ± 0.6 at 100 µM fluoxetine \[S+\] and \[R−\]). Imipramine and amitriptyline had less effect on gA channel lifetimes (τ~AD,15~/τ~cntrl,15~ = 1.4 ± 0.1 and 1.5 ± 0.1, and τ~AD,13~/τ~cntrl,13~ = 1.5 ± 0.1 and 1.6 ± 0.1 at 100 µM imipramine and amitriptyline). The citalopram enantiomers had the least effect (τ~AD,15~/τ~cntrl,15~ = 1.9 ± 0.2 and 1.78 ± 0.04, and τ~AD,13~/τ~cntrl,13~ = 2.0 ± 0.2 and 1.8 ± 0.1 at 250 µM citalopram \[S+\] and citalopram \[R−\]). There was no apparent stereospecificity, because the R enantiomers of fluoxetine and citalopram had similar effects on the AgA(15) and gA^−^(13) channel lifetimes, as did their S counterparts. The order of drug potency and the lack of enantiomer specificity agree with the results from the fluorescence quench assay.

Amitriptyline, imipramine, and the citalopram enantiomers had similar effects on the two gA channel types. That is, the drug-induced changes in τ did not vary with changes in the channel--bilayer hydrophobic mismatch (*l* -- *d*~0~). The two fluoxetine enantiomers, however, had greater effects on the shorter gA^−^(13) channels, with the greater hydrophobic mismatch, than on the longer AgA(15) channels ([Fig. 7 C](#fig7){ref-type="fig"}).

The implications of this different dependence on hydrophobic mismatch were explored using the theory of elastic bilayer deformations ([@bib35]; [@bib62]; [@bib61]; [@bib69]). The deformation induced by the formation of the transmembrane channel, with its associated energetic cost, causes the bilayer to impose a disjoining force (*F*~dis~) on the channel, which is the sum of contributions due to the hydrophobic mismatch and to the intrinsic curvature ([@bib69]):$$F_{dis} = 2 \cdot H_{B} \cdot \left( {d_{0} - l} \right) - H_{X} \cdot c_{0},$$where *H*~B~ and *H*~X~ are phenomenological elastic coefficients that are functions of the bilayer material properties and channel radius and *c*~0~ the intrinsic curvature. The curvature-dependent contribution to *F*~dis~ does not depend on the channel--bilayer hydrophobic mismatch and will therefore be the same for channels of different lengths (e.g., the channels formed by AgA(15) and gA^−^(13)). The normalized changes in the lifetimes of the short gA^−^(13) (τ~AD,13~/τ~cntrl,13~) and the long AgA(15) (τ~AD,15~/τ~cntrl,15~) channels therefore can be expressed as ([@bib54]; [@bib69]; [@bib15]):$$\frac{\tau_{{AD},13}}{\tau_{{cntrl},13}} = \frac{\tau_{{AD},15}}{\tau_{{cntrl},15}} \cdot \exp\left\{ \frac{2\delta \cdot \left( H_{B}^{AD} - H_{B}^{cntrl} \right) \cdot \left( l_{13} - l_{15} \right)}{k_{B}T} \right\},$$where *l*~13~ and *l*~15~ denote the lengths of the short gA^−^(13) channel (∼1.9 nm) and the long AgA(15) channel (∼2.2 nm). Using [Eq. 12](#e12){ref-type="disp-formula"}, we deduce that changes in bilayer elasticity will produce relatively greater changes in the lifetimes of the short gA^−^(13) channels (compared with the AgA(15) channels). When evaluating the drug-induced changes in *H*~B~, we find that 100 µM fluoxetine (*S*+) or (*R*−) decreases *H*~B~ by ∼2.3 ± 0.5 *k*~B~*T*/nm^2^ and ∼3.0 ± 0.3 *k*~B~*T*/nm^2^ (*H*~B~ for the unmodified bilayer is ∼22 *k*~B~*T*/nm^2^; [@bib54]). 100 µM imipramine decreases *H*~B~ by only ∼1.3 ± 0.9 *k*~B~*T*/nm^2^. The remaining three compounds had negligible effects at their highest tested concentrations and would, within the framework provided by the theory of elastic bilayer deformations, be deemed to primarily alter the intrinsic curvature (*c*~o~).

When considered as a group, the differential effects of ADs on the lifetimes of gA^−^(13) and AgA(15) channels are similar to those of other compounds ([@bib55]; [@bib69], [@bib70]; see [Fig. 8](#fig8){ref-type="fig"}). [Fig. 8](#fig8){ref-type="fig"} A shows results for the ADs (colored symbols) as well as previously published results for other compounds (in gray).

![**Comparing changes in gA^−^(13) lifetimes with AgA(15) lifetimes for a library of compounds. (A)** Changes in gA^−^(13) channel lifetimes versus the corresponding changes in AgA(15) channel lifetimes. Gray dots represent previously published data ([@bib55]; [@bib69], [@bib70]); colored symbols represent different concentrations of the ADs amitriptyline (purple), imipramine (pink), fluoxetine (S+; red), fluoxetine (R−; orange), citalopram (S+; blue), citalopram (R−; green). Values are mean ± SE of ln(normalized τ); *n* ≥ 3. DC~18:1~PC/*n*-decane. Slope of the straight line fit is 1.17 ± 0.02, with residuals shown in Fig. S3. **(B)** Histogram of slopes from straight line fits to individual compounds where the maximum lifetime change is at least 150% of the control lifetimes for both gA^--^(13) and AgA(15) at maximum concentration. The width of the distribution suggests that some compounds alter bilayer properties other than elasticity. If fitted with a Gaussian distribution, the mean is 1.12, with a SD of 0.06.](JGP_201812263_Fig8){#fig8}

The distribution of the slopes for the different compounds is shown in [Fig. 8 B](#fig8){ref-type="fig"} together with a Gaussian fit. The distribution of slopes suggest that the ADs alter lipid bilayer properties by a combination of thermodynamic softening (e.g., [@bib23]; [@bib83]; [@bib15]), which does not depend on molecular features (other than the drug's partial molar area in the bilayer--solution interface), and more specific interactions with the bilayer-forming lipids.

Discussion {#s13}
==========

The TCA and SSRI families of ADs are promiscuous modifiers of membrane protein function (Table S1). We explored a possible mechanism for this promiscuity: that the amphiphilic ADs partition into lipid bilayers and thereby alter their properties. We find that the TCAs and SSRIs indeed alter lipid bilayer properties, as demonstrated by their effects on gA channel activity. These changes were observed with gA channels of opposite handedness and drugs of opposite chirality, effectively ruling out direct binding. This provides a mechanism for the ADs' ability to alter the function of many different membrane proteins. Specifically, we show that these compounds reduce the lipid bilayer contribution to the free energy cost of membrane protein conformation transitions. The 21 tested compounds varied widely in their potencies to alter gA channel function, reflecting different partitioning into the bilayer and different intermolecular interactions in the bilayers. The relative potencies correlated with *K*~1~ (and cLogP), but not with cLogD~7~. Channel function increased twofold at a drug mole fraction in the bilayer of 0.02--0.07 ([Table 2](#tbl2){ref-type="table"}), corresponding to 0.2--0.7 drug molecules in the first lipid shell around the channels.

We first discuss the basis for how ADs alter lipid bilayer properties and the concentrations at which they do so. We finally consider briefly the implications for drug development.

The molecular basis for AD effects on bilayer properties {#s14}
--------------------------------------------------------

Amphiphiles may alter lipid physical properties (thickness, intrinsic curvature, and the associated elastic moduli) by at least three nonexclusive mechanisms. First, when amphiphiles intercalate into the bilayer interface, they will alter the profile of intermolecular forces across the bilayer ([@bib71]; [@bib16]), which in turn will lead to changes in acyl chain dynamics, elastic moduli, and intrinsic curvature ([@bib30]). Second, the reversible partitioning of amphiphiles into the bilayer will increase the bilayer area, reduce the apparent elastic moduli ([@bib23]; [@bib83]), and most likely also thin the bilayer, because the increase in surface area is likely to occur without much increase in the volume of the hydrophobic core, which in turn will alter the intrinsic curvature (e.g., [@bib44]; [@bib18]; [@bib28]). Third, in the case of membrane protein--induced deformations, the local bilayer deformation will lead to a redistribution of the amphiphiles in the vicinity of the protein (e.g., [@bib14]), which also will lead to an apparent softening ([@bib3]) or an increase in the thermodynamic elasticity ([@bib23]; [@bib83]).

The first mechanism involves the amphiphile's detailed molecular structure and position in the bilayer. The second two mechanisms are thermodynamic in origin and therefore less dependent on the molecular structure. Whatever the (dominant) mechanism, however, it is unlikely that an amphiphile will alter only one bilayer property. The dihydrochalcone phloretin, for example, is a promiscuous modifier of membrane protein function that partitions into lipid bilayers to alter the interfacial dipole potential ([@bib2]), but it also increases the permeability to neutral solutes ([@bib2]) and the bilayer elasticity ([@bib36]). The changes in the gramicidin monomer↔dimer equilibrium (the changes in $\Delta G_{Bilayer}^{M\rightarrow D}$ for the transition) reflect the aggregate effects of all the amphiphile-induced changes in bilayer properties (except for changes in fluidity, which do not alter $\Delta G_{Bilayer}^{M\rightarrow D}$). It is possible to get insight into the underlying mechanisms, however, using the resolution provided by single-channel experiments (e.g., [Fig. 8](#fig8){ref-type="fig"}), which shows that even when amphiphiles are known to alter the intrinsic curvature, the changes in curvature may not be the quantitatively most important contributors to the changes in $\Delta G_{Bilayer}^{M\rightarrow D}$; rather, the increase in the thermodynamic elasticity (compare [Fig. 8](#fig8){ref-type="fig"}) will in many cases become the dominant term ([@bib53]).

If all AD molecules had the same propensity to alter bilayer properties (per molecule in the membrane), and the differences in *D*~AD~ only reflected different partitioning, then there should be a straight-line relationship between log(*D*~AD~) and log*K*~1~ with a slope of −1. The slopes of the fits to the log*K*~1~−log(*D*~AD~) and clogP−log(*D*~AD~) relations are indeed indistinguishable from −1, meaning that the relative bilayer-modifying potency of different ADs depends primarily on their relative partition coefficients into the bilayer. This conclusion is consistent with the results of Ingolfsson and Andersen (2011) and [@bib82] on normal and fluorinated alcohols but in contrast with the results on a series of analogues of the snail toxin 6-bromo-2-mercaptotryptamine dimer, which showed no correlation between drug partitioning into the bilayer and their bilayer-modifying potency.

Many structurally unrelated compounds, such as detergents, lipid signaling molecules and metabolites, phytochemicals ([@bib40], [@bib42]; [@bib54]), alcohols ([@bib39]), and drugs ([@bib69], [@bib70]; this study), produce similar changes in gA channel function. Given that gA channels are small, approximating smooth cylinders, it is unlikely that all of the above compounds have specific binding sites with similar affinities; rather, they exert their effects by altering lipid bilayer properties. Moreover these unrelated compounds have a commonality: they alter the function of both gA channels and integral membrane proteins ([@bib54]), and the changes in membrane protein function can be related to the changes in gA channel function. This commonality arises despite the differences between the gA monomer↔dimer transition and the conformational changes that underlie the function of integral membrane proteins, indicating that both gA channels and integral membrane proteins respond to similar changes in lipid bilayer properties.

Despite the gA channels' simplicity, their energetic coupling to their host bilayer is complex, as highlighted by the differential effects of amphiphiles on elasticity versus curvature in single-channel electrophysiology experiments using gA channels of different lengths. In the case of the fluoxetine enantiomers, we observed greater effect on the channel with greater hydrophobic mismatch, meaning they altered bilayer elasticity. In contrast, for amitriptyline, imipramine, and the citalopram enantiomers, we observed similar effects on gA channels irrespective of their length, suggesting that they primarily altered intrinsic curvature.

Following [@bib23], amphiphiles will be expected to increase bilayer elasticity for thermodynamic reasons. Indeed, most compounds tested to date have a dominant effect on elasticity, as shown by the slope of \>1 when comparing normalized lifetimes of short and long channels ([Fig. 8 A](#fig8){ref-type="fig"}), though the distribution of slopes ([Fig. 8 B](#fig8){ref-type="fig"}) suggests that molecular features also are important. This is also likely to be true for amitriptyline, imipramine, and citalopram, where the dominant changes in bilayer properties appear to be curvature, an effect that is more dependent on the molecular features than on the amphiphilic nature of the compound per se. A compound's effect on $\Delta G_{def}$, and thus the bilayer contribution to the free energy of a membrane protein conformational change ([Eq. 1](#e1){ref-type="disp-formula"}), will depend on changes in both curvature and elasticity but with varying apportionment of the two properties. To further understand the molecular basis for these observations, one will need to examine a library of diverse and complex molecules in conjunction with computational and spectroscopic studies on the changes in lipid bilayer head group and acyl chain organization and dynamics.

AD concentrations {#s15}
-----------------

Micromolar concentration of TCAs and SSRIs are sufficient to alter the function of a transmembrane protein (the gA channel), at the concentrations where these drugs have promiscuous effects on many different channels. Given the simplicity of our experimental system, a single-component bilayer with a small yet very well-defined channel, one may question to what extent our conclusions extend to more complex systems. In this context it is important to note that there are no qualitative differences between our results in the single-component bilayers, which allow for detailed mechanistic interpretation, and our results in more complex membranes, in the presence of cholesterol ([@bib14]; [@bib69]; [@bib31]), or in membranes formed by so-called raft-forming mixtures ([@bib32]). Moreover, it is possible to relate the amphiphile-induced changes in function of channels formed by integral membrane proteins, whether purified and reconstituted or expressed in cell membranes, to the corresponding changes in gA channel function in single-component bilayers ([@bib52], [@bib53], [@bib54]; [@bib74], [@bib75]; [@bib69]; [@bib31], [@bib32]; [@bib43]). That is, though the gating mechanisms of channels formed by integral membrane proteins and gA channels are different, they are sensitive to the same changes in bilayer properties. In cases where there is no correlation between the effects in cells and in the gA-based assays (e.g., [@bib32]; [@bib20]), the parsimonious interpretation becomes that the compounds alter membrane protein function by direct interactions or binding to their target.

Electrophysiological and transport studies involving more complex cellular membrane systems, which show that TCAs and SSRIs alter the function of large variety of membrane proteins (Table S1) at concentrations similar to those where the drugs alter gA channel function, thus need to be interpreted with caution. Though one cannot exclude that the changes in membrane protein function involve specific interactions (binding to a target protein), an alternative interpretation would be that at least a portion of the observed effects may reflect "nonspecific" drug--bilayer interactions (changes the $\Delta G_{bilayer}$ contribution to $\Delta G_{total}$). Indeed, the parsimonious interpretation of results that demonstrate a promiscuous drug's effects on multiple, unrelated membrane proteins' function at similar concentration is that these effects reflect changes in the common feature shared by all membrane proteins: their host lipid bilayer.

Plasma concentrations of ADs are in the 0.1--1 µM range, with ∼90% being protein bound ([@bib19]; [@bib26]), which are less than the concentrations used in our and many other in vitro experiments. However, as has been demonstrated previously ([@bib46]; [@bib13]), the concentration of fluvoxamine and fluoxetine in relevant therapeutic compartments, such as the brain, is 10- to 20-fold higher than plasma concentrations (up to 10 µM). Moreover, at clinically relevant concentrations, Δ*G*~def~, and ergo the bilayer contribution to membrane protein function, though small, will be nonzero. Such small Δ*G*~def~ may be undetectable by our short-term assay but may nevertheless alter cell and system function when administered chronologically. For example, modifying less than ∼1% of voltage-dependent sodium channels with pyrethroid insecticides is sufficient to induce hyperexcitatory states ([@bib60]).

Implications for AD drug development {#s16}
------------------------------------

The crystal structure of the biogenic amine transporter with a variety of compounds reveals a binding pocket where SSRIs and TCAs exert their inhibitory effects on these proteins ([@bib79]). The drugs' inhibitory effects (with *K*~i~s in the nanomolar range) on these proteins, however, do not provide the sole explanation for their clinical effects. Depression is increasingly modeled as a complex disease that is impacted by the immune system, hypothalamic--pituitary axis, neurotrophins, neurotransmitter changes, and synaptic and neural network plasticity, among other factors, all of which are targets for AD therapies ([@bib78]; [@bib21]).

In this context, it may be important that ADs are promiscuous drugs, and resolving the molecular basis for drug promiscuity may help guide drug development toward either a "magic bullet" (targeting one specific protein) or a "magic shotgun" (targeting multiple proteins; [@bib68]; [@bib34]; [@bib12]; [@bib64]; [@bib67]). Targeting multiple molecular pathways and networks, rather than individual proteins (i.e., exploiting drug promiscuity \[or polypharmacology\]) has proven advantageous (e.g., [@bib17]), though the molecular properties that confer polypharmacological promise also may confer risk of toxicity ([@bib64]). Polypharmacology can be achieved by different means, but a common feature of amphiphilic drugs is that they partition into the lipid bilayer/solution interface and thereby alter lipid bilayer properties. If the changes in bilayer properties are sufficiently large, then this is likely to cause toxicity; more modest changes may alter system function ([@bib22]). The qualitatively different effects of fluoxetine and imipramine on the one hand and amitriptyline and citalopram on the other suggest that it may be possible to design molecules to target a bilayer property that may be important for a subset of membrane protein families.
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